# BeiGene expands US manufacturing and R&D campus in Hopewell, New Jersey

BeiGene announced the last structural steel placement at its Hopewell, New Jersey campus, a $700 million facility for commercial-stage biologic pharmaceutical manufacturing and R&D, expected to be complete in 2024.

- Type: Expansion
- Announced: 2023-03-21
- Where: Hopewell, New Jersey, United States
- Value: $700.0M
- Jobs: 100
- Starts operating: 2024
- Status: under construction
- Capacity: 400,000 sq ft manufacturing space, expandable to 1,000,000 sq ft
- Products: biologic pharmaceutical medicines
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [BeiGene](https://endata.com/companies/43012.md)

## Sources

- [citybiz.co](https://www.citybiz.co/article/394650/beigene-enters-new-phase-to-expand-us-manufacturing-and-rd-footprint-in-new-jersey/), 2023-03-21: "Adding these manufacturing and R&D capabilities in the U.S. is a major step toward fulfilling our vision to create impactful medicines that will be affordable and accessible to far more cancer patients around the world."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.